subscribeSubscribe
Merck-Gilead`s weekly HIV combo maintains viral suppression

Merck-Gilead`s weekly HIV combo maintains viral suppression
FIERCE BIOTECH
07 Mar 2024
Share Share
Data Presented at EACS 2023 Demonstrate Strong Profile of Twice-Yearly Sunlenca

Data Presented at EACS 2023 Demonstrate Strong Profile of Twice-Yearly Sunlenca
BUSINESSWIRE
20 Oct 2023
Share Share
Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir

Gilead Sciences Announces New Clinical Trial in Europe to Assess Lenacapavir
BUSINESSWIRE
18 Oct 2023
Share Share
Twice-Yearly Lenacapavir Shows Sustained Impact on Quality of Life

Twice-Yearly Lenacapavir Shows Sustained Impact on Quality of Life
BUSINESSWIRE
24 Jul 2023
Share Share
Gilead Sciences` Sunlenca (lenacapavir) Approved In Europe

Gilead Sciences` Sunlenca (lenacapavir) Approved In Europe
EMA
27 Jun 2023
Share Share
Gilead Presents Data for Combination Regimen of Lenacapavir with Antibodies

Gilead Presents Data for Combination Regimen of Lenacapavir with Antibodies
BUSINESSWIRE
22 Feb 2023
Share Share
FDA approves Gilead`s long-acting HIV injectable Sunlenca

FDA approves Gilead`s long-acting HIV injectable Sunlenca
Zoey Becker FIERCEPHARMA
23 Dec 2022
Share Share
FDA Approves New HIV Drug for Adults with Limited Treatment Options

FDA Approves New HIV Drug for Adults with Limited Treatment Options
PRNEWSWIRE
22 Dec 2022
Share Share
Gilead`s Sunlenca (Lenacapavir) Receives Approval in Europe

Gilead`s Sunlenca (Lenacapavir) Receives Approval in Europe
EMA
25 Aug 2022
Share Share
Gilead`s twice-yearly HIV med snags first nod after FDA rebuff

Gilead`s twice-yearly HIV med snags first nod after FDA rebuff
Angus Liu FIERCEPHARMA
23 Aug 2022
Share Share